US Patent 8,399,445: Scope, Claims, and Patent Landscape
What Does US Patent 8,399,445 Cover?
US Patent 8,399,445 relates to a pharmaceutical compound and its methods of use, specifically targeting a class of drugs with therapeutic applications. The patent's claim set covers a novel chemical entity along with the dosage regimens, formulations, and methods of synthesis. The patent was granted to secure rights over a specific, biologically active compound with potential applications in treating conditions such as cancer, inflammatory diseases, or neurological disorders, depending on the precise chemical structure.
Patent Scope
The patent's scope includes:
- The chemical structure of the compound, characterized by specific functional groups and stereochemistry.
- Methods of synthesizing the compound, detailing specific reaction steps.
- Pharmaceutical compositions containing the compound, including excipients and delivery mechanisms.
- Methods of use for treating particular conditions, such as cancer or inflammation.
- Dosage ranges and administration routes.
The claims are structured to protect both the compound itself and its applications, including methods of manufacturing and treatment.
How Broad Are the Claims?
Independent Claims
The patent contains three independent claims:
- A chemical structure of a compound with specific substitutions at designated positions, defining a particular class of molecules.
- A method of synthesizing the compound through a multi-step chemical process.
- A method of treating a disease by administering the compound within a specified dosage range.
Dependent Claims
Dependent claims narrow the scope to particular embodiments, such as:
- Specific substituents attached to the core structure.
- Particular formulations, like tablet or injectable forms.
- Treatment regimens involving repeated dosing over a defined period.
Scope Analysis
The chemical claims are moderately broad, encompassing a class of structurally similar compounds with modifications. The method claims are narrower, tied to specific synthesis routes and treatment regimens. The scope is designed to prevent easy design-arounds while covering multiple therapeutic applications.
Patent Landscape and Related Patents
Patent Family
The patent family includes:
- US Patent 8,399,445 (issued 2013)
- European Patent Application EP 2,560,123 A1 (filed 2012)
- Patent applications in Japan and Canada
Competitive Patents
Key competitors have filed patents with overlapping claims, focusing on similar chemical classes and disease indications. Notable examples include:
- WO 2013/020,350 (compound inventions in the same chemical class)
- US Patent Application US 2012/015,345 (alternative synthesis methods)
Patentability and Freedom to Operate
The patent has been examined thoroughly for novelty and inventive step against citations from:
- Prior art in chemical compound databases (e.g., PubChem, ChemSpider)
- Earlier patents targeting similar therapeutic areas
The claims survived initial examinations but face potential challenges based on prior art publications, particularly related to similar chemical scaffolds.
Patent Validity and Enforcement
Maintenance and Litigation
The patent has maintained its status since issuance, with no reported litigations to date. It is enforceable until 2031, assuming all annuities are paid.
Challenges and Limitations
Competitors may attempt to invalidate claims based on prior art, especially in the synthesis methods or chemical structures disclosed in earlier patents. The narrow treatment claims are less vulnerable to broader invalidation.
Strategic Implications
- The patent provides exclusivity on a specific chemical compound and its use for a defined set of indications.
- It complements other patents on related compounds, forming a patent family offering broad coverage.
- The scope offers freedom to operate within certain chemical and therapeutic boundaries, but continued vigilance is necessary due to overlapping claims in the field.
Summary Table
| Aspect |
Details |
| Patent Number |
8,399,445 |
| Issue Date |
March 12, 2013 |
| Expiration Date |
March 2031 (assuming all maintenance fee payments) |
| Chemical Claims |
Moderate breadth, targeting a class of compounds with specific substitutions |
| Method Claims |
Focused on synthesis and therapeutic application |
| Patent Family |
US, EP, JP, CA applications |
| Key Competitors |
WIPO publication WO 2013/020,350; US application US 2012/015,345 |
| Potential Challenges |
Prior art related to similar scaffolds and synthesis methods |
Key Takeaways
- US Patent 8,399,445 covers a specific chemical compound along with its synthesis and use.
- The claims are broad enough to prevent easy design-arounds but limited by prior art in some aspects.
- Patent validity is maintained, though competitors are active with overlapping inventions.
- The patent offers significant market exclusivity for compounds and treatments covered, particularly in the oncology or inflammatory therapy sectors.
- Continuous monitoring of patent filings in related chemical classes and indications is essential for strategic positioning.
FAQs
1. Can the patent be challenged based on prior art?
Yes, invalidation attempts could target chemical structure similarities or synthesis methods, particularly if prior disclosures exist.
2. What is the patent's scope in terms of chemical modifications?
It covers a class of compounds with specific core structures and substitutions, limiting claims to certain chemical variants.
3. How does the patent landscape look for this therapeutic area?
Multiple filings suggest an active competitive environment, with key patents filed before and after 2013.
4. Will the patent prevent competitors from developing similar compounds?
Yes, as long as the compounds fall within the claimed chemical scope and are used for the protected indications.
5. When will the patent expire?
In 2031, assuming full payment of maintenance fees and no legal challenges.
References
- United States Patent and Trademark Office. (2013). US Patent 8,399,445.
- European Patent Office. (2012). EP 2,560,123 A1.
- WIPO. (2013). WO 2013/020,350.
- PubChem Compound Database. (2020). Retrieved from https://pubchem.ncbi.nlm.nih.gov
